Like other single-gene disorders, muscular dystrophy displays a range of phenotypic heterogeneity even with the same primary mutation. Identifying genetic modifiers capable of altering the course of muscular dystrophy is one approach to deciphering gene-gene interactions that can be exploited for therapy development. To this end, we used an intercross strategy in mice to map modifiers of muscular dystrophy. We interrogated genes of interest in an interval on mouse chromosome 10 associated with body mass in muscular dystrophy as skeletal muscle contributes significantly to total body mass. Using whole-genome sequencing of the two parental mouse strains combined with deep RNA sequencing, we identified the Met62Ile substitution in the dual-specificity phosphatase 6 (Dusp6) gene from the DBA/2 J (D2) mouse strain. DUSP6 is a broadly expressed dual-specificity phosphatase protein, which binds and dephosphorylates extracellular-signal-regulated kinase (ERK), leading to decreased ERK activity. We found that the Met62Ile substitution reduced the interaction between DUSP6 and ERK resulting in increased ERK phosphorylation and ERK activity. In dystrophic muscle, DUSP6 Met62Ile is strongly upregulated to counteract its reduced activity. We found that myoblasts from the D2 background were insensitive to a specific small molecule inhibitor of DUSP6, while myoblasts expressing the canonical DUSP6 displayed enhanced proliferation after exposure to DUSP6 inhibition. These data identify DUSP6 as an important regulator of ERK activity in the setting of muscle growth and muscular dystrophy.
Introduction
Muscular dystrophies, like most Mendelian disorders, arise from mutations in single genes that associate with variable penetrance and expressivity. In addition to environmental effects, genetic factors contribute to phenotypic variability, and discovering genetic modifiers for single gene disorders defines pathways that may be exploited for prognostic and therapeutic purposes. Mutations within the genes encoding the dystrophin glycoprotein complex cause muscular dystrophy and genetic modifiers have been identified that influence these forms of muscular dystrophy (1) (2) (3) . Limb-girdle muscular dystrophy type 2C (LGMD 2C) arises from mutations that disrupt the γ-sarcoglycan (SGCG) gene. SGCG is a dystrophin associated protein and its null mutations lead to a similar phenotype as dystrophin mutations in Duchenne muscular dystrophy (DMD) (4, 5) , although considerable phenotypic variability is present even with the same single primary SGCG mutation (5) . Thus, additional factors influence disease outcomes in muscular dystrophy.
To identify genetic modifiers, quantitative trait locus (QTL) mapping has been applied to the Sgcg mouse model of LGMD2C (6) (7) (8) . Sgcg mice were generated by deleting exon 2, which creates a null mutation, and like their human counterparts with LGMD 2C, Sgcg mice have muscle membrane disruption, loss of myofibers, extensive muscle fibrosis and accompanying cardiomyopathy (9) . A backcross strategy was used to show that genetic background strains in mice confer mild and severe phenotypes to the Sgcg mouse (6) . The DBA/2J (D2) strain exacerbates features of muscular dystrophy in mice and this has been shown for both Sgcg mice as well as mdx mice, the model for DMD (6, 10, 11) . In the D2 strain, muscular dystrophy models have more muscle weakness, increased muscle fibrosis and greater Evans blue-dye uptake, a marker of muscle membrane fragility (10, 12) . The D2 strain is also associated with impaired muscle regeneration in muscular dystrophy (10, 11) . Diminished muscle regeneration, in concert with the progressive degeneration in muscular dystrophy, is thought to contribute to the overall smaller muscle size in muscular dystrophy in the D2 strain (6) . This is in contrast to what is observed in wild-type (WT) non-dystrophic mice, where the D2 strain is larger (13) .
Using an intercross of Sgcg-null mice from the severe D2 and mild 129 background strains (8) , two different modifiers have been identified for muscular dystrophy (7, 14) . The first modifier discovered through this approach was Ltbp4 (7) . A 36 bp in-frame deletion was identified in Ltbp4 from the D2 background. Ltbp4 encodes latent TGFβ binding protein 4 (LTBP4) and the 36 bp deletion removes 12 amino acids from LTBP4's hinge region, resulting in increased release of latent TGFβ and increased TGFβ activity (7) . Furthermore, single-nucleotide variants in human LTBP4 associate with duration of ambulation in DMD boys, indicating LTBP4 modifies muscular dystrophy in both mice and humans (15, 16) . A second modifier was also discovered using QTL mapping in Sgcg mice. A cryptic splice variant in Anxa6 was identified encoding a truncated annexin A6 protein that negatively modifies membrane repair (14) .
We now examined QTL mapping data for body mass in the context of muscular dystrophy and identified an interval on chromosome 10 that contributes to body mass. We identified a variant in the dual-specificity phosphatase 6 (Dusp6) gene within this interval that correlated with body mass. The DUSP6 protein belongs to a family of mitogen-activated protein kinase (MAPK) phosphatases that specifically target and dephosphorylate MAPK/extracellular signal-regulated kinase (ERK) to negatively regulate this pathway (17) (18) (19) . ERK activation associates with cell proliferation in multiple cell types including muscle (19) (20) (21) (22) . In this study, we show that a missense variant in Dusp6 correlates with a partial loss of function of DUSP6 activity, thus promoting ERK activity. Furthermore, we show that treatment with a specific DUSP6 inhibitor leads to increased proliferation in myoblasts from the 129 but not D2 background. These findings identify DUSP6 as a target for regulating myoblast proliferation and muscle growth.
Results

Chromosomal loci associated with body mass in muscular dystrophy
The D2 mouse strain intensifies the phenotypes of muscular dystrophy compared with the 129 T2/SvEmsJ (129) mouse strain (6, 10, 11) . To identify genetic regions influencing distinct properties related to muscular dystrophy, QTL mapping was carried out on a previously described F3 intercross of Sgcg-null mice from the D2 and 129 background strains (8) . QTLRel was used to associate genetic intervals with total body mass from an F3 cohort of 189 mice (23) . Two loci were identified with P-values ≤ 0.05. The first locus on chromosome 1 maps to an interval harboring the Mstn locus, which encodes myostatin, a profound regulator of body mass (24) . A second locus on chromosome 10 was also found to be significantly associated with body mass (Fig. 1A) . The 95% confidence interval for this region on chromosome 10 locus ranges from 40.67-54.96 cM (Fig. 1B and C) .
Genetic background influences body and muscle mass
To evaluate whether strain differences modify mass, WT and Sgcg-null mice from the D2 and 129 strains were weighed and muscles were harvested at 14-15 weeks of age. For both WT male and females, D2 mice had significantly increased body mass compared with 129 mice. These findings are consistent with those reported on genetic background strains from the Jackson Laboratories (13) . The increase in body mass conferred by the D2 strain was diminished in Sgcg muscular dystrophy mice indicating the dystrophic process itself alters body mass ( Fig. 2A) . Individual skeletal muscles were isolated and assessed for mass. In WT mice, females but not males exhibited increased muscle mass in D2 mice compared with 129 mice for the quadriceps and gastrocnemius muscle, illustrating that muscle is not the only determinant of the strain-dependent body mass differences in mouse strains. In muscular dystrophy models, the D2 strain exacerbates muscular dystrophy resulting in smaller muscles (6) . Consistent with this prior observation, in the Sgcg muscular dystrophy muscle, the mass of individual muscles was significantly reduced by the D2 background compared with Sgcg mice in the 129 mice background strain ( Fig. 2B and C) . Similar to skeletal muscle, the heart showed strain-dependent differences in size. In the WT backgrounds, there was increased mass of the left ventricle (LV) and right ventricle (RV) in male D2 mice compared with male 129 mice (P = 0.01 and P = 0.03, respectively) (Supplementary Material, Fig. S1 ). Similar trends were seen for the LV in female mice, with D2 LV mass exceeding 129 LV mass (P = 0.07).
In skeletal muscle, we examined cross-sectional area (CSA) and fiber number as reflections of hypertrophy and hyperplasia, both of which contribute to mass. In WT quadriceps muscles, CSA was significantly increased (P = 0.04) in D2 compared with 129 but this difference was not seen in Sgcg-null dystrophic muscle from the two background strains. Fiber number was similar between WT D2 and WT 129 fast muscles, but Sgcgnull D2 quadriceps muscles had significantly reduced fiber number compared with Sgcg-null 129 (P = 0.002) (Supplementary Material, Figs S2A and S3A). We also evaluated the slow-twitch soleus muscle and found that CSA was similar between WT D2 and WT 129 soleus muscles, but in Sgcg-null dystrophic muscle, Sgcg-null D2 CSA was significantly smaller than Sgcg-null 129 (P < 0.0001). In soleus muscle, fiber number was increased in WT D2 compared with WT 129 (P = 0.01), and this difference was lost when comparing Sgcg-null D2 and Sgcg-null 129 soleus muscle fiber number (Supplementary Material, Figs S2B and S3B). Thus, the strain-dependent effects of background differ on fast and slow muscle, but muscular dystrophy is sufficient to override the genetic modifiers that normally make the D2 strain larger than the 129 strains.
Candidate modifier genes in the chromosome 10 interval
In order to identify candidate genetic modifiers of body mass, genomic differences between strains were identified and filtered icantly increased body mass compared with 129 mice in the WT background but not in the Sgcg-null background (males, P < 0.0001; females, P < 0.0002). In WT mice, the quadriceps (B) and gastrocnemius (C) muscles were larger for female mice but not for males in the D2 compared with the 129 background strain (P = 0.011 female quadriceps and P = 0.006 female gastrocnemius). Conversely, muscle mass was significantly decreased in Sgcg-null D2 mice compared with Sgcg-null 129 mice for both quadriceps (males and females; P < 0.0001) and gastrocnemius (males P = 0.0004; females P = 0.0002). Comparisons by two-tailed student's t-test. in a step-wise manner using whole-genome sequence data comparing the parental D2 and 129 strains (8) (Supplementary Material, Fig. S4 ). Genomes from both the D2 and 129 strains were first aligned to the C57BL/6J (B6) mouse reference genome, version mm10 using the MegaSeq workflow and then compared (25) . Protein-coding genes within the QTL interval were then assessed for nonsense and missense polymorphisms. Missense variations within canonical transcripts were further filtered and ranked based on whether they were predicted to be deleterious to protein function using the sorting intolerant from tolerant (SIFT) algorithm (26) . RNA-sequencing data from muscle was used to compare expression difference. Variants were then validated using Sanger sequencing. The chromosome 10 QTL region contains a total of 136 protein-coding genes, 45 of which contained 172 missense and nonsense protein-coding variants when comparing between the D2 and 129 parental strains. Using SIFT to assess the potential effect on proteins, 11 missense variants were considered deleterious across six genes. Using RNAseq, only three of these genes had relatively high expression in skeletal muscle, including Dusp6 (Table 1) .
DUSP6 as a candidate genetic modifier for body mass on chromosome 10
DUSP6 belongs to a family of phosphatases responsible for regulating the MAPK/ERK pathway (27, 28) . The MAPK/ERK strain but not in other common mouse strains. Met62Ile is also conserved in human DUSP6 and overall this domain, which mediates ERK binding, is highly conserved.
(B) Genotypes of SNPs flanking the Dusp6 region from a cohort of more than 175 intercross Sgcg F3 mice from a Sgcg D2 X Sgcg 129 cross (14) . SNPs flanking DUSP6, JAX00187391 and UNC101149923, from the F3 Sgcg intercross were analyzed for their association with body mass. Their relative position to Dusp6 is shown on the top bar. Mice with the D2 genotype at both markers showed significant association with increased body mass (P = 0.044, P = 0.042). The most proximal marker to Dusp6, JAX00187391, showed a significant association between the D2 genotype and increased quadriceps muscle mass (P = 0.003). Comparisons by one-way ANOVA. (C) A GST-pulldown assay was performed to measure the interaction between ERK and DUSP6 using the ERK2 binding domain. DUSP6 Met62Ile displayed a significantly reduced interaction with ERK2 compared with DUSP6 Met62 (P = 0.0009, n = 3, two-tailed student's t-test.).
pathway is a central regulator of cell growth and differentiation and DUSPs regulate the MAPK pathway through their rapid dephosphorylation activity (19) . DUSP6 is a highly specific negative regulator of this pathway through its dephosphorylation of ERK2 in the cytoplasm, which then inhibits translocation of ERK2 to the nucleus (29) . We identified a Dusp6 variant unique to the D2 strain, rs13480726, based on genome assembly GRCm38.p5 (Chromosome 10:99263877, c.186G > A, p.Met62Ile). The D2 strain has an isoleucine substituted for the methionine at position 62, and the D2 strain is the only mouse strain exhibiting this variant. The methionine at position 62 is highly conserved across species (Fig. 3A) . Furthermore, this position falls directly within the ERK2-interaction domain that was previously mapped to amino acids 61-69 (30) . Site directed mutagenesis of amino acids 63-65 was previously shown to result in loss of the direct interaction between DUSP6 and ERK2 (30) . The loss of DUSP6 binding by ERK2 had the net effect of increasing ERK2 activity (30) . We examined the genotypes of QTL single nucleotide polymorphism (SNP) markers, JAX00187391 and UNC101149923, as these flanked the Dusp6 gene and were informative in the Sgcg F3 intercrossed cohort. Sgcg mice harboring the D2 SNPs in this chromosome 10 interval had increased body and quadriceps mass compared with the mice carrying SNPs derived from the 129 strains. Furthermore, the most proximal informative SNP to the Dusp6 gene itself, JAX00187391, has the strongest association with increased mass compared with UNC101149923 (Fig. 3B) . These data indicate that while overall, the D2 strain results in smaller muscles in muscular dystrophy mice, this effect is driven by other loci in the D2 genome. The genetic association data support that the Dusp6 locus counteracts the overall D2 background effect and stimulates larger mass.
To test whether the Met62Ile substitution modified DUSP6's ability to interact with ERK2, we analyzed ERK2 binding with a mutated DUSP6 interaction domain (amino acids 1-154) using a Glutathione S-transferase (GST) pulldown assay. We found that substitution of Met62 with an isoleucine reduced binding by ∼2-fold compared with the canonical DUSP6 interaction domain (Fig. 3C) . We also evaluated the intracellular localization by transfecting GFP-tagged Met62Ile and Met62 DUSP6 into C2C12 cells. The Met62Ile substitution did not alter the cytoplasmic localization of DUSP6 nor its overall expression level indicative of similar protein stability when overexpressed in C2C12 cells (Supplementary Material, Fig. S5 ). Thus, the Met62Ile variant through a reduced ERK2 interaction is expected to enhance ERK2 phosphorylation and activity.
Increased phosphorylated ERK1/2 from the Met62Ile substitution in DUSP6
To assess the activity of DUSP6 harboring the Met62Ile substitution, we overexpressed DUSP6 with either methionine or isoleucine at position 62. Plasmids were introduced into C2C12 myoblasts and phosphorylation of ERK1/2 was monitored. A 50% increase in phosphorylated ERK1/2 (pERK) was seen in cells transfected with DUSP6 Met62Ile compared with cells transfected with DUSP6 Met62 (Fig. 4A) . pERK levels were normalized to the amount of transfected DUSP6 in addition to input lanes to account for any differences in transfection efficiencies. No significant differences were observed for total ERK protein. Thus, the Met62Ile DUSP6 substitution showed a partial loss of function accounting for increased pERK and sustained pERK activity.
To assess whether pERK levels were changed in vivo, we assessed pERK levels in quadriceps muscles isolated from WT and muscular dystrophy mice from the D2 and 129 backgrounds. In the WT background, a trend toward increased pERK levels was seen for D2 mice (Fig. 4B, left) . A 20% decrease in pERK levels was observed in Sgcg muscle from the D2 strain compared with Sgcg muscle from the 129 strains (Fig. 4B, right) . No significant differences were observed for total ERK protein. To understand this result, we examined Dusp6 gene expression in dystrophic muscle. RNA-sequencing data from WT and Sgcg-null quadriceps muscles was used to compare Dusp6 gene expression from D2 and 129 mouse strains. We found that Dusp6 transcript expression was significantly higher in D2 muscle compared with 129 in the WT backgrounds and that an even larger difference was seen in the Sgcg-null backgrounds (Fig. 4C) . Immunoblotting was used to monitor DUSP6 protein in muscle. In the WT background, we detected similar amounts of DUSP6 protein between D2 and 129 muscles (Fig. 4D, left) . However, the Sgcg-null muscle from the D2 background showed a 350% increase in DUSP6 protein (Fig. 4D,  right) . Together, these results indicate that while the Met62Ile substitution reduces DUSP6's binding by approximately half, in the setting of muscular dystrophy, the 350% upregulation of DUSP6 protein is sufficient to largely compensate for the partial loss of function.
Inhibition of DUSP6 results in increased myoblast proliferation
In muscle progenitor cells, ERK activation promotes cell proliferation (19) . BCI (2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride), also known as NSC 150117, is a highly specific inhibitor of DUSP6 and was previously shown to prevent DUSP6-mediated pERK dephosphorylation by acting as an allosteric binding inhibitor in the phosphatase domain (31) . We examined whether there was differential sensitivity to BCI between D2 and 129 myoblasts, as would be expected from the Met62Ile substitution in Dusp6. Myoblasts isolated from the D2 and 129 strains were treated with a range of concentrations of BCI (0, 0.5 and 2 μm) and then assessed for cell growth at multiple time points. Myoblasts from the 129 strains showed a dose-dependent increase in proliferation, consistent with the known activity of BCI, which by inhibiting DUSP6 activity promotes ERK activity (31) . This effect was seen in myoblasts isolated from WT and Sgcg muscular dystrophy mice. In contrast, myoblasts from the D2 strain were resistant to BCI. At 0.5 μm and 2.0 μm BCI, myoblasts from the D2 strain showed little to no effect on myoblast growth from both WT and Sgcg mice ( Fig. 5A and B) . For both strains and genotypes, at higher concentrations of BCI (5.0 and 7.5 μm), myoblast proliferation was suppressed, suggestive of toxicity (Supplementary Material, Fig. S6 ). These data demonstrate a differential sensitivity to BCI where myoblasts from 129 strains respond to DUSP6 inhibition by BCI, whereas BCI has little effect on DUSP6 with the Met62Ile substitution, as this form already exhibits compromised function.
Discussion
MAPK/ERK as a modifier of mass
The MAPK/ERK pathway responds to a wide range of growth factors/mitogens and stress stimuli to send intracellular signals. Of the major MAPK pathways, the ERK1/2 pathway has been extensively linked to cell growth and proliferation through its role in regulating cell cycle progression. Once activated, ERK1/2 phosphorylates a wide range of intracellular substrates to regulate proliferation, differentiation and apoptosis (22) . Studies in multiple different tissues such as skin, skeletal muscle and the heart have shown that loss of ERK1/2 signaling can inhibit proliferation. In myoblasts, fibroblast growth factor-stimulated ERK1/2 signaling is required for proliferation (32) (33) (34) . Furthermore, ERK1/2 signaling has been shown to regulate hypertrophy in skeletal muscle (35) . In mouse cardiac muscle, transgenic activation of ERK1/2 signaling promotes cardiac hypertrophy (36, 37) . In order to regulate both the magnitude and duration of these responses, MAPK phosphatases such as DUSP6 play a critical role by inactivating of ERK1/2 signaling, often with high specificity to more precisely regulate ERK signaling (30) .
We now identified naturally occurring variation in the Dusp6 gene in the DBA2J (D2) mouse genome as a modifier of body mass. This specific variant (Met62Ile) is only present in the D2 mouse strain and has not been reported in other mouse or human SNP databases. However, there is one heterozygous Met62Val allele of 238 244 alleles in the Genome Aggregation Database (gnomAD) (MAF 4.197e-6). In humans, there are no loss of function variants in DUSP6 in the Exome Aggregation Consortium (ExAC) (constraint metric pLI = 0.91) and missense variants are lower than expected (constraint metric z = 2.72), indicating a comparatively low tolerance to variation. Although identified in the context of mouse muscular dystrophy, in principle, this effect should not be restricted to muscular dystrophy and may apply more broadly to tissue growth. We identified a missense variant that alters a methionine in the ERK binding domain of DUSP6. Prior studies implicated this same region as being essential to ERK binding and site directed mutagenesis in neighboring residues showed reduced interaction between DUSP6 and ERK (30) . Perturbing DUSP6 binding to ERK was similarly associated with increased ERK phosphorylation and activity (30, 38) . Intriguingly, QTL mapping studies for mass, size and weight gain in pigs implicated a genomic locus that included porcine DUSP6, suggesting this pathway is active in other mammals beyond mice (39) . Mice engineered to lack Dusp6 had increased heart mass and fibroblasts and showed reduced apoptosis (40) . In this model, Dusp6-null mice had improved cardiac compensation after myocardial injury (40) . Furthermore, increased cardiomyocyte proliferation has been observed in Dusp6-null zebrafish as well as zebrafish treated with DUSP6 inhibitors (31, 41) . Together, these findings suggest a relationship between growth and DUSP6/ERK signaling in a number of cell types.
We found that the Dusp6 genotype was associated with skeletal muscle mass, indicating that Dusp6 likely regulates muscle mass in the same manner it can affect other cell types and tissues. We found that inhibition of DUSP6 activity increased proliferation of myoblasts from the 129 strains, which harbors a more canonical DUSP6 sequence. In contrast, the D2 strain, which carries the Met62Ile variant in DUSP6, failed to increase myoblast proliferation and was effectively resistant to inhibitors of DUSP6 activity. These data indicate that myoblasts are one cell type responsive to DUSP6 regulation of ERK1/2 and it is possible that both hyperplastic and hypertrophic mechanisms contribute to the effect of DUSP6 in muscle.
Is promoting mass in muscular dystrophy through ERK signaling beneficial?
It is widely believed that increasing muscle mass can benefit muscular dystrophy since increased mass is expected to convey increased strength. Loss of myostatin, the negative regulator of muscle mass improves muscle strength and reduces fibrosis in the mdx mouse model of Duchenne muscular (42) . In humans, a previous clinical trial utilizing a myostatin antibody treatment shows trends of increased muscle mass and ambulation (43) . Gene delivery of follistatin, a potent myostatin antagonist, also showed similar positive effects on muscle mass and ambulation (44) . However, promoting muscle mass without sufficiently enhancing muscle regeneration in muscular dystrophy may also result in increased muscle damage due to excessive force production in an already weakened muscle. Specifically, in a canine model of DMD, myostatin inhibition led to unequal muscle growth and greater contractures (45) . Muscle-specific overexpression of follistatin in dysferlin-deficient mice exacerbated muscle degeneration (46) . We now found that inhibition of DUSP6 promoted myoblast growth in genetically susceptible mice, but it remains to be seen whether this effect is helpful in a dystrophic context.
A complexity of the current study is that the effect on growth was more evident in WT animals than it was in muscular dystrophy animals, where much of the effect on growth was reversed presumably because of the influence of many other genomic loci in the DBA2J background, which overall inhibits muscle growth in muscular dystrophy (6) . QTL mapping in mice has shown that growth in normal animals is under the influence of many different genomic intervals (47, 48) . Most QTL studies are conducted in WT mice, and the course of muscular dystrophy, with ongoing degeneration and regeneration, is a process that systemically activates many MAPK pathways. Consistent with the concept that DUSP6 itself is important for muscle function, and perhaps injury response, it has been shown that rapid upregulation of ERK1/2 signaling occurs in human skeletal muscle in response to exercise (49, 50) . Thus, the upregulation of ERK signaling occurs in normal muscle and mediates multiple responses after acute exercise. In dystrophic muscle, where there are many distinct cell types including myoblasts, fibroblasts, immune infiltrate cells and myofibers, ERK signaling may be more essential for some cell types compared with others. Taken together, these data show that a genetic variant associated with an ERK-modifying phosphatase differentially impacts myoblast proliferation and muscle growth in mice according to their genetic background, thus emphasizing the need to better decipher the genetic interactions instructing muscle homeostasis in normal and diseased conditions.
Materials and Methods
Ethics statement
Mice were housed and treated according to protocols approved by the Northwestern University's Institutional Animal Care and Use Committee. Mice were euthanized using carbon dioxide, cervical dislocation and removal of the heart. Methods were optimized for the reduction of pain and discomfort.
Mouse strains and QTL mapping
Sgcg mice were previously generated by deletion of exon 2 to create a null allele of Sgcg (9) . Sgcg mice were then backcrossed into the DBA2J (D2) and 129 T2/SvEmsJ (129) backgrounds for more than 10 generations and then intercrossed to generated Sgcg D2/129 animals (8). A previously described intercross was conducted between Sgcg 129 and Sgcg D2 mice (14) . Approximately 180 F3 intercrossed mice Sgcg 129/D2 were analyzed for body mass, muscle mass, fibrosis and Evans blue-dye uptake as described (8) . QTL mapping was carried out using the Mouse Universal Genotyping Array and analyzed by QTLrel (23) to identify loci of interest. WT and Sgcg mice from the D2 or 129 backgrounds were analyzed and harvested at 14-15 weeks of age.
Whole-genome sequencing
Whole-genome sequencing of D2 and 129 mice was previously described (14) . Genomes were now aligned to the mouse genome assembly mm10. Coding variants were assessed for predicted deleterious effect using the SIFT algorithm (26) .
Plasmids
The plasmid encoding Dusp6 was engineered with a carboxyterminal Myc-DDK-tag (Origene Rockville, MD USA; Cat# MR222688). Site-directed mutagenesis was performed to create Dusp6 variants. The DUSP6 interaction domain was amplified from resulting plasmids and cloned into a PGEX-4 T-3 GST vector (GE Life Sciences Marlborough, MA USA; Cat#28-9545-52). The Mapk1 plasmid was engineered with a carboxy-terminal Myc-DDK-tag (Origene Rockville, MD USA; Cat# MR227633).
Cell isolation, culture and transfections
C2C12 cells (ATCC Manassas, VA USA; Cat# CRL-1772) were grown in Dulbecco's Modified Eagle Medium with 10% fetal bovine serum and 1% penicillin/streptomycin in 5% CO 2 . Primary mouse myoblasts were isolated from hind limb muscles of 6-to 8-week-old mice using a previously described protocol (51) . Myoblasts were grown in Ham's F-10 Nutrient Mixture (F-10) supplemented with 20% FBS, 2% penicillin/streptomycin and 10 ng/μl of fibroblast growth factor (Miltenyi Biotec Bergisch Gladbach, Germany Cat# 130-093-842) in 5% CO 2 . C2C12 cells were plated at ∼70-80% confluency in a 60 mm dish with Opti-MEM Reduced Serum Media prior to transfection. Transfections used Lipofectamine 3000 Transfection Reagent (ThermoFisher Rockford, IL USA; Cat# L3000008). The p3000 reagent was used at a 2:1 P3000:DNA ratio to transfect 10 μg of desired plasmids into C2C12 cells. Cells were transfected overnight and replaced with growth media the following morning and were allowed to grow for 48 h prior to protein isolation. BCI ((E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; 3-(cyclohexylamino)-2,3-dihydro-2-(phenylmethylene)-1Hinden-1-one; 2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride and also known as NSC 150117) was purchased as a lyophilized powder (Axon Med Reston, VA USA Cat#2178) and resuspended in DMSO. Approximately 3000 cells from each strain were plated in triplicates in 96 well plates and treated with BCI at varying concentrations (0, 0.5 and 2 μm) in 0.1% DMSO myoblast growth medium. Media was replaced with fresh media containing BCI every 48 h. Cells were imaged and analyzed for relative cell density at multiple time points using the IncuCyte plate imager.
Muscle fiber counts and cross-sectional analysis
Muscles were placed in 10% formaldehyde (ThermoFisher Rockford, IL USA; Cat#245-684) and embedded into paraffin. Sections from the center of the tissue were stained with hematoxylin and eosin (Newcomer Supply Middleton, WI USA; Cat#12013B; Cat#1070C). Whole muscle sections were imaged using an Axio Observer A1 microscope (Zeiss, Germany) using Zen software (Zeiss, Germany) with a 10× objective. Total muscle fiber counts were quantitated using FIJI (NIH Bethesda, MD USA). Fiber CSA was quantitated using FIJI (NIH Bethesda, MD USA) for quadriceps (vastus-intermedius) and soleus. n ≥ 3 male mice per group.
Immunoblotting
Mice were euthanized at approximately 14-15 weeks of age. Quadriceps muscles were isolated and immediately placed in tissue lysis buffer (2 mm Ethylenediaminetetraacetic acid (EDTA), 50 mm HEPES pH 7.5, 150 mm NaCl, 10 mm NaF, 10 mm Na-pyrophosphate, 10% glycerol, 1% Triton X-100 and Roche cOmplete protease inhibitor). Tissue was homogenized using a homogenizer (BioSpec Bartlesville, OK USA) and subsequently the Bio-Rad Bradford reagent was used to measure protein concentration. Tissue lysates were separated using a 4-15% Mini-PROTEAN pre-cast gel and transferred to a Polyvinylidene Difluoride Immobilon-P membrane (EMDMillipore Burlington, MA USA; Cat# IPVH00010). StartingBlock T20 TBS (ThermoFisher Rockford, IL USA; Cat# 37543) was used for blocking and incubation of antibodies. The anti-phosERK1/2 antibody was used at 1:2000 (Cell Signaling Danvers, MA USA; Cat#9101S). The anti-ERK1/2 antibody was used at 1:2000 (Cell Signaling Danvers, MA USA; Cat#9102S). The anti-DUSP6 antibody (Origene; Cat# TA301017) was used at 1:1000. The anti-Myc antibody was used at 1:1000 (Origene Rockville, MD USA; Cat#TA150014). The anti-GST antibody was used at 1:1000 (ThermoFisher Rockford, IL USA; Cat# MA4-004). Goat anti-mouse and anti-rabbit antibodies conjugated to horseradish peroxidase were used at 1:2000. Memcode membrane stain (ThermoFisher Rockford, IL USA; Cat# 24585) was used to detect total protein. The actin protein band at 43 KDa was used as the loading control. Image analysis was performed using ImageJ.
RNA-seq analysis
The Illumina TruSeq RNA Sample Prep Kit version 2.0 was used to generate RNA sequencing libraries from quadriceps muscles from three D2 and three 129 mice. The RNA samples were indexed with unique adapters and pooled for 100 bp pairedend sequencing using the Illumina HiSeq 2000. RNA-seq reads were aligned using TopHat v2.0.2 to the mouse genome assembly mm10. Transcripts were assessed and quantitated using HT-seq and analyzed for differential expression using EdgeR. Counts per million (CPM) were used to calculate differential expression. Heatmaps were made from Z-scores calculated from log transformed CPM values per gene.
Protein purification and GST pulldown
The PGEX-4 T-3 plasmid containing Met62 and Met62Ile DUSP6-GST was transformed into ROSETTA competent cells (EMDMillipore Burlington, MA USA; Cat# 70954-3). Bacteria was grown to an OD 600 of 0.8 and then induced with 0.5 mm of IPTG for 2 h at 37
• in a shaking incubator. DUSP6-GST protein was isolated using a GST spin purification kit (ThermoFisher Rockford, IL USA; Cat# 16107). ERK2 protein fused to a Myc tag was purchased from Origene (Rockville, MD USA; Cat# MR227633). Equal amounts of Met62 or Met62Ile DUSP6-GST were incubated with ERK2 and rotated overnight at 4
• C in binding/washing buffer (50 mm Tris (pH 7.5), 0.1 mm EDTA, 1% Triton X-100, 10% glycerol, 1 mm PMSF and 1 mm DTT). To pull down GST, Glutathione agarose beads (ThermoFisher Rockford, IL USA; Cat# 16100) were added the next day and allowed to incubate for 2 h at 4
• C and then washed with the washing buffer. Samples were eluted by incubation with Laemmli sample buffer (Biorad Hercules, CA USA; Cat# 161-0737) and boiling for 5 min. Samples were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Immunoblotting was done against Myc to detect ERK2-Myc and against GST to detect DUSP6-GST as a loading control.
Statistical analysis
GraphPad Prism was used and statistical tests were selected based on data distribution.
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Supplementary Material is available at HMG online. 
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